false 0001595893 0001595893 2021-04-09 2021-04-09

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 9, 2021

TURNING POINT THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

 

 

Delaware

 

001-38871

 

46-3826166

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

10628 Science Center Drive, Suite 200, San Diego, CA

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 926-5251

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value
per share

 

TPTX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934  (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 

 

 


 

 

Item 1.01.  Entry into a Material Definitive Agreement.

On April 9, 2021, Turning Point Therapeutics, Inc. (the “Company”) entered into an Office Lease (the “Lease”) with Gateway Torrey Hills LLC (“Landlord”) for the lease of approximately 20,679 square feet of rentable area of the building located at 3580 Carmel Mountain Road, San Diego, California 92130 (the “Premises”). The commencement date of the Lease is expected to be May 24, 2021.  The Company plans to use the Premises for general office use.  The term of the Lease (the “Term”) is 25 months. The minimum rent payable by the Company under the Lease will be approximately $101,327 per month for the first year of the Lease, with a one month abatement, and $105,876 per month for the remainder of the Term. The Company will also be responsible for the payment of additional rent to cover the Company’s share of increases in the annual operating expenses and annual tax expenses of the building over such expenses incurred in the base year ending June 30, 2021. In the event of a default of certain of the Company’s obligations under the Lease, Landlord would have the right to terminate the Lease and recover certain unpaid rent and expenses.

A copy of the Lease is filed as Exhibit 10.1 to this report and the foregoing description is only a summary of the material terms of the Lease, and does not purport to be complete and is qualified in its entirety by reference to such exhibits.

 

Item 2.03.  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit
No.

  

Description

 

 

10.1

 

 

Lease dated April 9, 2021 by and between Turning Point Therapeutics Inc and Gateway Torrey Hills LLC.

 

 

 

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

TURNING POINT THERAPEUTICS, INC.

 

 

 

 

Date: April 13, 2021

 

 

 

By:

 

/s/ Annette North

 

 

 

 

 

 

Annette North

 

 

 

 

 

 

Executive Vice President and General Counsel

 

 

 

 

 

Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Turning Point Therapeutics Charts.
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Turning Point Therapeutics Charts.